Table 2.
Clinical Features by Monoclonal Product
| Variable | All | Bamlanivimab | Casirivimab/Imdevimab |
|---|---|---|---|
| No. (%) | 594 | 479 (80.6) | 115 (19.4) |
| Age, mean (SD), y | 65 (13) | 65 (13) | 66 (15) |
| Female, No. (%) | 240 (40.4) | 186 (38.8) | 54 (47.0) |
| Race, No. (%) | |||
| American Indian or Alaska Native | 3 (0.5) | 3 (0.6) | 0 (0) |
| Asian | 5 (0.8) | 4 (0.8) | 1 (0.9) |
| Black or African American | 4 (0.7) | 3 (0.6) | 1 (0.9) |
| Native Hawaiian or Pacific Islander | 15 (2.5) | 14 (2.9) | 1 (0.9) |
| White | 548 (92.3) | 440 (91.9) | 108 (93.9) |
| Ethnicity | |||
| Hispanic or Latinx | 70 (11.8) | 55 (11.5) | 15 (13.0) |
| Communities of colora | 99 (16.7) | 80 (16.7) | 19 (16.5) |
| Total comorbidities, median (IQR) | 5 (3–6) | 5 (3–6) | 4 (3–5) |
| Individual comorbidities, No. (%) | |||
| Immunosuppressionb | 34 (5.7) | 28 (5.8) | 6 (5.2) |
| Diabetes mellitus | 390 (65.7) | 317 (66.2) | 73 (63.5) |
| Coronary artery disease | 82 (13.8) | 66 (13.8) | 16 (13.9) |
| Active malignancy | 23 (3.9) | 17 (3.5) | 6 (5.2) |
| Chronic pulmonary disease | 347 (58.4) | 282 (58.9) | 65 (56.5) |
| Chronic kidney disease | 188 (31.6) | 153 (31.9) | 35 (30.4) |
| Chronic liver disease | 170 (28.6) | 136 (28.4) | 34 (29.6) |
| Cerebrovascular disease | 117 (19.7) | 97 (20.3) | 20 (17.4) |
| Hypertension | 537 (90.4) | 435 (90.8) | 102 (88.7) |
| Chronic neurological disease | 0 (0) | 0 (0) | 0 (0) |
| Congestive heart failure | 145 (24.4) | 126 (26.3) | 19 (16.5) |
| Cardiac arrhythmia | 294 (49.5) | 237 (49.5) | 57 (49.6) |
| Obesityc | 397 (66.8) | 335 (69.9) | 62 (53.9) |
| Hours from test to infusion, median (IQR) | 53 (49–74) | 54 (49–74) | 52 (44–74) |
| Infusion location | |||
| Emergency department | 5 (0.8) | 5 (10.4) | 0 (0) |
| Infusion center | 272 (45.8) | 157 (32.8) | 115 (100) |
| Urgent care | 317 (53.4) | 317 (66.2) | 0 (0) |
| Infusion-associated adverse events | |||
| Any | 7 (1.2) | 6 (1.3) | 1 (0.9) |
| Mild | 5 (0.8) | 4 (0.8) | 1 (0.9) |
| Severed | 2 (0.3) | 2 (0.4) | 0 (0) |
| Outcomes | |||
| Emergency department visit (14 d) | 71 (12.0) | 62 (12.9) | 9 (7.8) |
| Hospital admission (14 d) | 23 (3.9) | 22 (4.6) | 1 (0.9) |
| Mortality (14 d) | 1 (0.2) | 1 (0.2) | 0 (0) |
| Composite outcome (14 d) | 75 (12.6) | 65 (13.6) | 10 (8.7) |
Abbreviation: IQR, interquartile range.
aSelf-identification as non-White race or Hispanic/Latinx ethnicity.
bSolid organ or hematopoietic stem cell transplant recipient, HIV, or currently receiving chemotherapy.
cBody mass index ≥30 kg/m2.
dSevere adverse events defined as requiring referral to emergency department for management.